SOUTH SAN FRANCISCO, Calif., January 28, 2026--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology ...
Monthly infusions of an investigational product that encapsulates dexamethasone sodium phosphate into autologous erythrocytes (EryDex) appeared safe but did not significantly improve neurological ...
IntraBio Inc. today announced that results from its pivotal Phase III clinical trial evaluating levacetylleucine for the treatment of Ataxia-Telangiectasia (A-T) have been published in The Lancet ...
Mixed Response in Interim Positron Emission Tomography/Computed Tomography Leads to Detection of a Gastrointestinal Stromal Tumor in a Patient With Mediastinal Diffuse Large B-Cell Lymphoma ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment ...
Quince Therapeutics has disclosed outcomes from the Phase III ATTeST clinical trial of EryDex (dexamethasone sodium phosphate encapsulated in autologous erythrocytes) for treating ...
Levacetylleucine Could Become the First-Ever FDA-Approved Treatment for Ataxia-Telangiectasia FDA accepts sNDA for AQNEURSA® (levacetylleucine) for Ataxia-Telangiectasia — a rare, progressive ...
Ataxia telangiectasia (A-T) is a rare autosomal recessive disorder characterised by progressive cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency and heightened cancer susceptibility.
Levacetylleucine (Aqneursa) improved functioning in a phase III crossover trial of adults and children with ataxia-telangiectasia. Two patients had three treatment-emergent adverse events; none were ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results